Klin Onkol 2011; 24(Suppl 1): 34-38. DOI: 10.14735/amko20111S34.
Summary
Multiple myeloma (MM) is the second most common hematological cancer. It is a very heterogeneous disease characterized by large genomic complexity, recurrent amplifications and/or deletions in the genome leading to different clinical manifestations and survival of patients. Thus, genomics plays an important role in identifying agents responsible for pathogenesis, prognosis and disease stratification of MM.
